Addressing the Challenges of Alzheimer’s Agitation
Advancing IGC-AD1 in the CALMA trial—supporting patients and caregivers through science and compassion.
Our Science,
Our Commitment
IGC Pharma is a clinical-stage biotechnology company dedicated to advancing Alzheimer’s research through scientific rigor, technological innovation, and a strong commitment to patients and caregivers.
CALMA
CALMA is a multicenter Phase 2 clinical trial designed to evaluate the safety and potential efficacy of IGC-AD1 for treating agitation in participants with dementia due to Alzheimer's disease.
IGC-AD1
IGC-AD1 is IGC Pharma’s lead candidate—a partial CB1 receptor agonist with anti-inflammatory action, designed to address agitation associated with Alzheimer’s disease.
Artificial Intelligence
Our AI transforms multimodal data into actionable insights, empowering physicians with early Alzheimer’s prediction and more precise clinical decision support.
Latest Press Releases
Explore how IGC Pharma’s data, trials, and milestones are shaping a brighter future for Alzheimer’s care.
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
Together, we’re turning research into resilience, and innovation into care for millions worldwide.
People age 65 and older live with Alzheimer's disease today in the US1.
People are projected to have Alzheimer's disease by 2060 in the US 1.
Leading cause of death among all ages in the United States1.
Expected cost of Alzheimer’s and dementia by 2050 (in 2025 dollars) if no treatment or cure is available1.
Pipeline
IGC Pharma’s pipeline bridges breakthroughs from AI-enhanced
early detection to IGC-AD1 and beyond, advancing Alzheimer’s
treatment frontiers.
In-depth insights,
real impact
“Science Spotlight” reveals our latest Alzheimer’s research, breakthroughs, and care innovations.
Resources
for Caregivers
This guide offers compassionate, evidence-based support for families caring for someone with Alzheimer’s disease. Written by leading neuropsychologists and enriched with real caregiver stories, it provides practical tips, emotional strategies, and step-by-step advice to understand the condition, manage daily challenges, and support emotional well-being. Supported by IGC Pharma, the book empowers caregivers with tips, strategies, and step-by-step guidance to improve care while also protecting their own well-being.
Investing in the Future:
IGC Pharma stands with families and vulnerable groups, investing in research, education, advocacy and Alzheimer’s awareness.
- 2025 Alzheimer’s disease facts and figures. Alzheimers Dement. 2025;21(4):e70235. Published 2025 Apr 29. doi:10.1002/alz.70235